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A B S T R A C T   
The short arm of chromosome 16 (16p) is enriched for segmental duplications, making it susceptible to recurrent, 
reciprocal rearrangements implicated in the etiology of several phenotypes, including intellectual disability, 
speech disorders, developmental coordination disorder, autism spectrum disorders, attention deficit hyperac-
tivity disorders, obesity and congenital skeletal disorders. In our clinical study 73 patients were analyzed by 
chromosomal microarray, and results were confirmed by fluorescence in situ hybridization or polymerase chain 
reaction. All patients underwent detailed clinical evaluation, with special emphasis on behavioral symptoms. 16p 
rearrangements were identified in 10 individuals. We found six pathogenic deletions and duplications of the 
recurrent regions within 16p11.2: one patient had a deletion of the distal 16p11.2 region associated with obesity, 
while four individuals had duplications, and one patient a deletion of the proximal 16p11.2 region. The other 
four patients carried 16p variations as second-site genomic alterations, acting as possible modifying genetic 
factors. We present the phenotypic and genotypic results of our patients and discuss our findings in relation to the 
available literature.   
1. Introduction 
Congenital developmental anomalies and neurodevelopmental dis-
orders (NDDs) are frequently caused by recurrent, reciprocal micro-
deletions and microduplications (Deshpande and Weiss, 2018; 
Kaminsky et al., 2011). These genomic disorders arise from non-allelic 
homologous recombination (NAHR) following the misalignment of 
segmental duplications (SDs) (Antonacci et al., 2010; Chen et al., 2014; 
Linardopoulou et al., 2005; Marques-Bonet and Eichler, 2009; Shaw and 
Lupski, 2004; Stankiewicz and Lupski, 2002; Tai et al., 2016). Chro-
mosome 16 has one of the highest percentages [(approximately 10% of 
its sequence, ~7.8 megabase pairs (Mb) (Martin et al., 2004)] of SDs 
amongst the human chromosomes, clustered along the short arm (16p). 
This predisposes 16p to rearrangements, and the resultant recurrent 
copy number variations (CNVs) are implicated in various genomic dis-
orders (Cooper et al., 2011; Girirajan et al., 2012; Itsara et al., 2009; 
Kanduri et al., 2016; Sahoo et al., 2011; Sanders et al., 2011; Stefansson 
et al., 2014; Weiss et al., 2008). 
The most frequently affected recurrent CNV region is the proximal 
breakpoint 4–5 (BP4–BP5) region of 16p, associated with a micro-
deletion syndrome (OMIM #611913) and a reciprocal microduplication 
syndrome (OMIM #614671). The region is approximately 600 kilobase 
pairs (Kb) in size, located from genomic position ~29.6 to ~30.2 Mb (all 
genomic positions in the manuscript are according to assembly 
GRCh37/hg19). In close proximity lies a 95 Kb segment encompassing 
BOLA2 (OMIM *613183; a gene suspected to be relevant in early em-
bryonic development), which has undergone Homo sapiens-specific 
expansion relatively recently in human evolution, and has been sug-
gested to predispose the BP4–BP5 region to recurrent rearrangement 
(Nuttle et al., 2016). The CNVs are associated with a wide variety of 
neuropsychiatric phenotypes, growth abnormalities, skeletal abnor-
malities and other, less frequent congenital anomalies (Table 1). CNVs of 
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this region were initially ascertained in autism spectrum disorder (ASD) 
populations: an estimated 0.28–1% of patients carry BP4–BP5 CNVs 
(Fernandez et al., 2010; Hanson et al., 2015; Kumar et al., 2008; Walsh 
and Bracken, 2011; Weiss et al., 2008), and subsequent large studies 
identified the recurrent CNVs in 0.6–0.7% of patients with NDDs 
(Rosenfeld et al., 2010; Shinawi et al., 2010; Steinman et al., 2016). In 
large 16p11.2 CNV populations 90% or more of carrier children were 
found to have neuropsychiatric diagnoses; the prevalence of ASD has 
been reported between 15 and 25%, and in most cohorts the frequency 
of autistic-like features is even higher (Green Snyder et al., 2016; Han-
son et al., 2015). The proximal CNVs are furthermore associated with 
developmental coordination disorder (DCD), specific speech disorders, 
epilepsy, and an increased prevalence of sacral dimples (often with 
atypical features, which may signify the presence of occult spinal dys-
raphism) (D’Angelo et al., 2016; Green Snyder et al., 2016; Hanson 
et al., 2015, 2010; Owen et al., 2018; Shinawi et al., 2010; Steinman 
et al., 2016; Zufferey et al., 2012). Comparing the reciprocal CNVs, 
duplication carriers are more likely to have tremor, attention deficit 
hyperactivity disorder (ADHD) and other behavioral problems (aggres-
sion, outbursts, etc.), and they have an increased risk for psychosis and 
severe intellectual disability (ID). Deletion patients, on the other hand, 
have a higher incidence of ASD and speech and language disorders 
(Giaroli et al., 2014; Green Snyder et al., 2016; Hanson et al., 2015; 
Shinawi et al., 2010; Steinman et al., 2016). The prevalence of behav-
ioral disorders shows consistent increase with age in both groups (Ber-
nier et al., 2017). Furthermore, the reciprocal CNVs cause mirror 
phenotypes in terms of body mass index (BMI), head circumference (HC) 
and brain volume: deletion carriers present with obesity, significantly 
increased HC and global increased brain size; meanwhile duplication 
carriers have a tendency towards being underweight and microcephalic, 
Table 1 
Main phenotypic features of the proximal (BP4–BP5) 16p11.2 rearrangements.  
Phenotype Proximal 16p11.2 duplication Proximal 16p11.2 deletion 
Frequency P5 P6 P7 Phenotype Frequency P9 
Growth 
Short stature/Reduced BMI/Failure to thrive in infancy VFHPO – – – Obesity OHPO +
Head and neck 
Microcephaly 13–17%a – – – Macrocephaly 17%a – 
Sparse eyelashes and/or eyebrows VFHPO – + + Hypertelorism OHPO – 
Hypertelorism VFHPO – + + Other minor abnormalities of the eyes variable – 
Other minor abnormalities of the eyes variable + – – Eye convergence difficulties 11%a – 
Eye convergence difficulties 20%a + – – Broad forehead FHPO – 
Microtia VFHPO – – – Malar flattening FHPO – 
Other minor abnormalities of the ears variable + + + Other facial minor anomalies variable – 
Thin upper lip vermillion VFHPO – – –  
Other facial minor anomalies variable + + +
Skeletal abnormalities 
Scoliosis OHPO – – – Scoliosis OHPO – 
Arachnodactyly VFHPO – – – Hand polydactyly OHPO – 
Other abnormalities of the fingers and/or toes variable + + – Other abnormalities of the fingers and/or toes variable +
Neurology and behavior 
Intellectual disability 30.5%b/40%c + + + Intellectual disability 10%d +
Motor Delay VFHPO + + + Global Developmental Delay VFHPO +
Speech Delay 32%c + + + +
Speech articulation difficulties 30%a/19%c – n.a. n.a. Speech articulation difficulties 79%a – 
Phonological Processing Disorder 56%d – 
Developmental Coordination Disorder 47%c – – – Developmental Coordination Disorder 58%d – 
Abnormal agility 25%a – – – Abnormal agility 47%a – 
Muscular hypotonia ~40%a + + + Muscular hypotonia ~50%a – 
Muscle weakness 23–32%a + – – Muscle weakness 17–22%a – 
Tremor 18–43%a – – – Tremor 5–8%a – 
Hyperreflexia 32%a – – – Hyperreflexia 13%a – 
Hyporeflexia 31%a – – – Hyporeflexia 48%a – 
Seizures/Epilepsy 26–29%a – – + Seizures/Epilepsy 22–27%a – 
Neuroimaging abnormalities (EEG/CT/MRI) 40/31/55%a + n.a. n.a. Neuroimaging abnormalities (EEG/CT/MRI) 54/28/26%a – 
Reduced brain volume  + n.a. n.a. Overgrowth in posterior fossa  – 
Thinner corpora callosa – n.a. n.a. Thicker corpora callosa – 
Ventriculomegaly + n.a. n.a. Chiari I malformation – 
Attention Deficit Hyperactivity Disorder 24%c – – – Attention Deficit Hyperactivity Disorder 19%d – 
Autism Spectrum disorder 19%c – + + Autism Spectrum disorder 26%d – 
Anxiety Disorder 18%c – – – Anxiety Disorder 6%d – 
Mood Disorder OHPO – – – Mood Disorder  +
Additional features 
Café-au-lait spots 31%a – – – Café-au-lait spots 30%a – 
Sacral dimple 28%a – – – Sacral dimple 34%a – 
Congenital diaphragmatic hernia OHPO – – – Congenital diaphragmatic hernia OHPO – 
Heart defects infrequent – – – Heart defects OHPO – 
Developmental differences of the urinary tract infrequent – – – Developmental differences of the urinary tract  +
Abnormalities of the digestive system infrequent + – – Abnormalities of the digestive system OHPO – 
The phenotypic features of the presented patients are listed. P5 is currently 3 years old, therefore evaluation of developmental and behavioral symptoms is subject to 
change. n.a., not available; BMI, body mass index; EEG, electroencephalography; MRI, magnetic resonance imaging; CT, computer tomography; HPO, Human 
Phenotype Ontology (https://hpo.jax.org/app/); VFHPO, listed as very frequent (83–99%) in HPO; FHPO, listed as frequent (30–79%) in HPO; OHPO, listed as occasional 
(5–29%) in HPO. 
a Steinman et al. (2016). 
b D’Angelo et al. (2016). 
c Green Snyder et al. (2016). 
d Hanson et al., 2015. 
A. Lengyel et al.                                                                                                                                                                                                                                 
European Journal of Medical Genetics 63 (2020) 104027
3
and they have reduced brain volume measurements (Bijlsma et al., 
2009; Jacquemont et al., 2011; Qureshi et al., 2014; Shinawi et al., 
2010; Steinman et al., 2016; Tabet et al., 2012; Walters et al., 2010). The 
deletion is more often associated with abnormally shaped, thicker 
corpora callosa, overgrowth in the posterior fossa, Chiari I malforma-
tions and tonsillar ectopia, whereas duplication carriers are more likely 
to have thinner corpora callosa, decreased white matter volume and 
ventriculomegaly (Owen et al., 2018). 
Another recurrent region is the distal BP2–BP3 16p11.2 region, 
which is approximately 220 Kb spanning ~28.8–29.0 Mb. Phenotypes 
associated with the microdeletion include obesity, generalized over-
growth, various NDDs [ID, global developmental delay (DD), delayed 
speech and language development, ASD, seizures, ADHD], and less often 
congenital anomalies of other organ systems (Bachmann-Gagescu et al., 
2010; Barge-Schaapveld et al., 2011; Bochukova et al., 2010). A ten-
dency towards increased HC was also observed, along with mirroring 
BMI and HC reduction in the reciprocal duplication (Loviglio et al., 
2017b). 
Our clinical study focused on a cohort of 73 Hungarian children 
referred to genetic counseling with the combination of non-syndromic 
minor craniofacial anomalies, mild to moderate ID/DD, and other var-
iable neuropsychiatric symptoms. All were analyzed by array compar-
ative genomic hybridization (array CGH) after various other methods 
failed to uncover genetic etiologies. A surprisingly large portion of our 
cohort (9/73, and an additional parent) proved to carry CNVs of the 
short arm of chromosome 16, therefore we will focus on this subgroup of 
patients below. 
2. Methods 
Karyotypes were determined for all patients by analysis of 20 
Giemsa-stained metaphases each from standard 72-h peripheral blood 
lymphocyte cultures. Array CGH was performed on Roche/NimbleGen 
system [NimbleGen Array (CGX 1.4 M); NimbleGen MS 200 Microarray 
Scanner (Roche NimbleGen Inc., Madison, WI, USA); patients P1–P4, 
P10]; on Agilent qChip Post microarray [60K; Genomic Workbench 7.0 
analysis software; P5 and P9]; and on Agilent 180K oligo-array [Amadid 
023363; Genomic Workbench Lite Edition 6.5 analysis software (Agilent 
Technologies, Santa Clara, CA, USA); P6–P8]. Array CGH results were 
validated by FISH using 16p11.2 KCTD13 548 kb and 16p11.2 ATXN2L- 
LAT probes (Agilent SureFISH) in 100–100 metaphase and interphase 
cells; or by polymerase chain reaction (PCR). Deletion/duplication of 
16p11.2 (genomic positions 29.6–30.2 Mb) was confirmed by quanti-
tative multiplex PCR of short fluorescent fragments (QMPSF) analysis 
with the primers listed in Supplementary File 1, according to the pro-
tocol of NPHP1-QMPSF (Javorszky et al., 2017) with modifications 
(Carrington et al., 2015). Copy numbers were calculated based on the 
normalized peak areas following intra- and inter-sample normalization 
(Supplementary File 2). Parental origin was determined by linkage 
analysis, carried out with microsatellite markers between genomic po-
sitions 31.3 and 35.2 Mb of region 16p11.2. Fragment analysis was 
performed on ABI 3500 Genetic Analyzer (Applied Biosystems, Foster 
City, CA, USA), and results were evaluated using Peak Scanner Software 
2 (Thermo Fischer Scientific, Waltham, MA, USA). 
3. Clinical descriptions 
Patient 1 [P1; DECIPHER (Database of Chromosomal Imbalance and 
Phenotype in Humans Using Ensembl Resources) #411579] was 
referred to genetic counseling with a clinical diagnosis of ASD when he 
was 10 years old. His perinatal anamnesis was unremarkable. Somatic 
and psychomotor development was normal until the age of 2 years, at 
which time he presented sudden and striking developmental regression 
with the complete loss of expressive speech. He has macrocephaly and a 
tendency towards self-injurious behavior. Neurologic examination 
included a negative EEG and brain MRI. Family history is negative for 
NDDs and congenital anomalies. 
Patient 2 (P2) was referred at the age of three years with psycho-
motor delay, feeding difficulties, loss of speech, generalized muscular 
hypotonia and hypoplasia of the musculature, ataxia and dyssynergia, 
stereotypy and bruxism. Her perinatal anamnesis was normal. Stra-
bismus, sparse eyebrows and eyelashes, epicanthus, short neck, low 
posterior hairline and joint hypermobility were noted upon physical 
examination. Brain MRI showed signs of abnormal myelination. EEG, 
EMG and ENG tests were negative, as were metabolic screenings, MLPA 
analyses for Prader-Willi and Rett syndromes, and direct sequencing of 
MECP2 gene. Family history is negative. 
Patient 3 (P3, DECIPHER #411594; Fig. 1A) was diagnosed at the 
age of three years with delayed speech and language development 
(vocabulary consisted of about five words, receptive speech was less 
impaired), minor anomalies, polydactyly and gait imbalance. He was 
born at term with normal parameters from a pregnancy complicated by 
oligohydramnios. He had a high-pitched cry as an infant, and feeding 
difficulties due to severe muscular hypotonia. Blepharophimosis, small 
and low-set ears with abnormal morphology, single transverse palmar 
crease, joint hypermobility, genu valgum and pes planus were noted. He 
has mild conductive hearing impairment in his right ear. Family history 
is negative. 
Patient 4 (P4, DECIPHER #411578; Fig. 1B) was referred at two 
years of age with the suspicion of Prader-Willi syndrome due to psy-
chomotor delay, generalized muscular hypotonia, small hands and feet, 
genu varum, strabismus, severe obesity and polyphagia. She was born 
after 39 weeks of gestation complicated by maternal diabetes, and 
impending fetal asphyxia necessitating C-section. She weighed 5500 g 
and had Apgar scores of 7/8. At age two years her BMI was 32.8 kg/cm2, 
while her current BMI is 45.7 kg/cm2. Her weight and BMI curves have 
steadily been well above the age and sex matched 97th percentile. 
Additional findings were elevated serum triglyceride levels and normal 
bone density measurements. Psychological evaluation using the Brunet- 
Lézine test estimated one month delay in gross motor development, two 
months delay in hand-eye coordination, 13 months delay in social in-
teractions and 17 months delay in speech development. Her develop-
mental quotient was 74 at 25 months of age. FISH analyses targeting 
SNRPN gene and the 1p36 deletion, as well as methylation analysis for 
Prader-Willi syndrome, were negative. Both parents are overweight. 
Patient 5 (P5, DECIPHER #411596) had normal birth parameters 
and perinatal adaptation. Bilateral cryptorchidism was observed upon 
birth. He had apneic episodes and feeding difficulties in infancy, but 
exhibited average psychomotor development until he was 5 months old, 
when he lost the ability to hold his head, roll over and crawl. Around this 
time he was transported to a hospital due to dehydration, generalized 
lymphoedema, hepatomegaly, fluctuations in consciousness, horizontal 
nystagmus and mild facial asymmetry. Brain CT revealed cerebral at-
rophy and ventriculomegaly, but extensive examinations ultimately 
failed to explain his acute condition. Clinical genetic consultation noted 
a wide and depressed nasal bridge, epicanthus, high palate, facial 
asymmetry, clinodactyly of the 3.-5. toes on both feet, frontal bossing 
and low-set, protruding ears. P5 is currently 3 years old with global DD 
and absent speech. He has yet to undergo official psychological evalu-
ation, but the mother reports a recent change in behavior (he stopped 
reacting to his name, has abnormal temper tantrums, started presenting 
abnormal eating behavior, is not interested in toys and has a short 
attention span). P5’s parents are healthy, but the paternal grandmother 
and uncle have abnormal aggressive and impulsive behavior. 
Patients 6 and 7 are a pair of brothers born to a non-consanguineous 
couple. The index patient was the younger child, Patient 6 (P6), who was 
referred to genetic counseling due to psychomotor delay, muscular hy-
potonia and minor facial anomalies (prominent forehead, downslanted 
palpebral fissures, hypertelorism, sparse medial eyebrows, low-set, 
protruding ears and downturned corners of mouth). He was born after 
41 weeks of gestation, his birth parameters and perinatal adaptation 
were normal. He has mild ID and autism. His older brother, Patient 7 
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(P7), has similar facial characteristics with additional micrognathia and 
strabismus. He was born at term and had asymptomatic neonatal 
hypoglycaemia. His NDDs include epilepsy, autism, poor attention span 
and aggressive behavior. Their mother (P8) was healthy at the time of 
first referral, but has since died from cancer. She gave birth to seven 
children from three separate partners. We were unable to officially 
evaluate the mother from a neuropsychiatric standpoint, but the refer-
ring physicians perceived that she could have a behavioral disorder. 
Mutation analysis for fragile X syndrome was negative for both boys and 
their parents. The father and the three full siblings are reported healthy; 
the family is not in touch with the two half-siblings. 
Patient 9 (P9) was referred due to unilateral renal agenesis and 
global DD. He was born with normal parameters from a pregnancy 
complicated by hypertension. The solitary right kidney is structurally 
and functionally normal. He had feeding difficulties in infancy, but 
started gaining weight when he was 9 years old. His BMI (27.8 kg/m2) is 
currently above the 97th percentile for his age and sex, while his height 
is at the 10th percentile. His weight is unmanageable due to abnormal 
Fig. 1. Phenotypes of Patients 3, 4 and 10. A: Pa-
tient 3’s phenotype is dominated by speech delay, 
dyslalia, cognitive disability and conductive hearing 
loss. His somatic development is normal. B: Patient 
4’s phenotype is consistent with the distal 16p11.2 
deletion: obesity, polyphagia and developmental 
delay (speech and social interactions are most 
severely affected). She also has strabismus, relatively 
small hands and feet, and a tibia varus deformity. C: 
This child’s phenotype is dominated by an articula-
tion disorder, autism spectrum disorder and attention 
deficit hyperactivity disorder. Additional features 
include sensorineural hearing loss and scoliosis.   
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eating behavior. He had encopresis up to age 8 years, and has mild ID, 
short attention span, impaired ability to form peer relationships, ste-
reotypical hand movements and body rocking, strange habits (e.g. he 
refuses to say the “o” sound when reading aloud), and occasional 
aggressive behavior. According to thorough psychiatric evaluation, 
although he shows signs of both ADHD and ASD, his symptoms are likely 
the result of ID, short attention span and childhood emotional disorder. 
His father has multiple sclerosis; family history is otherwise negative. 
Patient 10 (P10, DECIPHER #411577; Fig. 1C) was referred with 
sensorineural hearing impairment, scoliosis, anal and tracheal stenosis, 
minor anomalies (joint hypermobility, 2–3 toe syndactyly and clino-
dactyly of the 5th fingers) and motor delay. He was born at term with a 
weight of 4500 g and length of 56 cm, and his Apgar scores were 9/10. 
He suffered clavicle fractures during delivery. His psychomotor and 
cognitive development is normal, but he has speech articulation diffi-
culties that require logopedic therapy. His current behavioral disorders 
include an impaired ability to form peer relationships and abnormal 
temper tantrums. Pediatric psychiatric evaluation diagnosed ASD and 
ADHD. Valproic acid (methylphenidate was rejected due to competitive 
sport activity) has led to noticeable improvement in his behavior. MRI of 
the brain was normal, meanwhile EEG showed frontotemporal epileptic 
lesions. His mother and his three brothers are dyslexic. One of the 
brothers has unilateral hearing impairment and unilateral renal 
hypoplasia. 
The clinical findings of the patients are summarized in Table 2. 
Informed consent was obtained from all patients, and additional permit 
to publish identifiable photographs was obtained from the parents of P4 
and P10. 
4. Results of array CGH 
We identified six pathogenic 16p CNVs in patients whose clinical 
phenotypes correspond to the literature, and in four further patients the 
16p deletion/duplication co-occurred with another CNV. Array CGH 
results are detailed in Table 3; the proximal and distal recurrent 16p 
CNV regions and our patients’ chromosomal abnormalities are visual-
ized on Fig. 2. Importantly, none of the presented patients have under-
gone whole exome/genome sequencing, therefore the possibility of 
unidentified pathogenic single nucleotide variants is considerable. 
4.1. Pathogenic chromosome 16p CNVs 
In the case of P4 array CGH revealed a 215.8 Kb loss of the distal 
BP2–BP3 16p11.2 region (16:28,824,802–29,040,571). Parental FISH 
examinations with a corresponding probe confirmed the maternal origin 
of the deletion. P4 has an additional likely benign deletion of 
2q37 (2:242,855,645–243,030,854; 175.2 Kb). In patient P5 we 
identified a 569.0 Kb large duplication of proximal 16p11.2 
(16:29,620,689–30,190,568), which corresponds to a pathogenic gain 
of the recurrent BP4–BP5 CNV region. The duplication was confirmed by 
FISH (Fig. 3A); inheritance of the CNV is uncertain: P5’s mother was 
proven to not be a carrier by PCR, but the father refused testing. A 
similar 574.6 Kb large gain of 16p11.2 (16:29,624,765–30,199,351) was 
detected in two brothers (P6, P7) and their mother (P8). Array CGH was 
normal for the father. Finally, P9 presented a deletion of the BP4–BP5 
region (16:29,656,684–30,190,568; 533.8 Kb). The loss was confirmed 
by PCR, and linkage analysis excluded its presence in the mother; the 
father refused testing. 
4.2. Multiple CNVs with 16p involvement 
Array CGH revealed two CNVs in P1: a 2.441 Mb large pathogenic 
duplication of 15q11.1q11.2 (15:20,207,363–22,671,977), and a 173.1 
Kb large deletion of 16p12.2 (16:21,566,709–21,739,799), which was 
interpreted as a variant of unknown significance (VUS). P2 has two 
CNVs as well, a 1.824 Mb large likely benign deletion of 5q13.2 
(5:68,830,621–70,654,255) and a VUS duplication of 16p12.2 
(16:21,953,152–22,480,514; 526.9 Kb). P3 carries a 102.1 Kb, likely 
benign deletion of 16p11.2 (16:28,722,783–28,824,859), and an addi-
tional 110.8 Kb deletion on Xq28 (X:153,409,765–153,520,551), clas-
sified as VUS. The proximal breakpoint of P3’s 16p11.2 loss is directly 
adjacent to the distal breakpoint of the BP2–BP3 recurrent region. The 
families of P1–P3 did not agree to further testing; therefore we were 
unable to perform segregation analyses. P10 is a carrier of two deletions: 
a 1.85 Mb loss of 16p11.2 (16:31,980,001–33,825,000; Fig. 3B), and a 
110.8 Kb deletion of Xq28 (X:153,409,765–153,520,551). The 16p11.2 
deletion was confirmed by PCR, and was proven to have arisen de novo 
by linkage analysis of the family (Fig. 3C and D). 
Supplementary File 3 summarizes the results of our database search 
relating to the altered regions of P1–P3 and P10; and Supplementary File 
4 lists the OMIM genes encompassed in their CNVs. 
5. Discussion 
5.1. Pathogenic recurrent CNV regions of chromosome 16p11.2 
The herein presented patients P5–P9 carry CNVs of the proximal 
BP4–BP5 region of 16p. Table 1 summarizes the phenotypic features of 
the proximal reciprocal CNVs, integrating the symptoms of patients from 
our cohort, and information from recent literature and online databases. 
(P8, mother of P6–P7, is not included due to limited available infor-
mation.) P5’s neurodevelopmental phenotype is in line with the dupli-
cation syndrome (OMIM #614671), however it remains unclear if (or to 
what extent) the CNV could be responsible for his previously detailed 
acute multi-system disease. The brothers (P6 and P7) show typical fea-
tures associated with the recurrent 16p11.2 duplication as well; P7 
presented a more severe phenotype with epilepsy. Their mother never 
had formal neuropsychiatric evaluations; however her suspected 
behavioral and social problems could be attributed to a milder form of 
the duplication syndrome. Patient P9’s phenotype corresponds to the 
reciprocal chromosome 16p11.2 deletion syndrome (OMIM #611913). 
Patient P4’s phenotype is likewise consistent with the distal 16p11.2 
microdeletion syndrome (OMIM #61344). P4 also has a deletion over-
lapping with the 2q37 microdeletion syndrome (OMIM #600430), 
characterized by mild-moderate ID/DD, brachymetaphalangy, short 
stature, obesity, hypotonia and characteristic facies (which P4 does not 
resemble). However, her loss is much smaller than the deletions of 
previously reported patients and does not include the HDCA4 gene 
(OMIM *605314), proposed to be a critical gene within the micro-
deletion (Aldred et al., 2004; Williams et al., 2010). We suggest P4’s 
phenotype was predominantly caused by the 16p11.2 deletion (inheri-
ted from her mother, who is obese, but mentions no history of NDDs); 
however a modifying effect of the 2q37 microdeletion cannot be 
excluded. 
Several genes within the regions have been implicated in the asso-
ciated phenotypes. A smaller, ~118 Kb deletion within the proximal 
recurrent region co-segregated with ASD/autistic features in a three 
generation family, refining a possible critical region for ASD that in-
cludes three candidate genes: MVP, SEZ6L2, and KCTD13 (Crepel et al., 
2011). SEZ6L2 (OMIM *616667) has been suggested to have a role in the 
modulation of neuronal differentiation (Boonen et al., 2016). MVP 
(OMIM *605088) has been linked to ADHD through transcriptome-wide 
association and mRNA expression profile analyses (Qi et al., 2019); has 
been shown to have a role in synaptic plasticity (Ip et al., 2018), and is 
known to interact with PTEN (OMIM *601728), a gene implicated in 
ASD/ID with macrocephaly (Loviglio et al., 2017b; Yu et al., 2002). 
KCTD13 (OMIM *608947) encodes a protein that is a substrate-specific 
adapter of a BTB-CUL3-RBX1 E3 ubiquitin ligase complex, which targets 
small GTPase RhoA for ubiquitination and degradation, and is necessary 
for normal synaptic transmission (Chen et al., 2009). The gene has been 
suggested to drive the mirror microcephaly/macrocephaly phenotypes 
in a zebrafish study (Golzio et al., 2012). This experimental finding was 
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Table 3 
Copy number variations identified in the presented patients.  
Patient Chromosome Band Type Start breakpoint (bp) End breakpoint (bp) Size (Kb) Origin Classification Disorder (OMIM#) 
P1 16p12.2 Del 21,566,709 21,739,799 173.1 n.a. VUS – 
15q11.1q11.2 Dup 20,207,363 22,671,977 2441.5 n.a. P 608636 
P2 16p12.2 Dup 21,953,152 22,480,514 527.4 n.a. VUS – 
5q13.2 Del 68,830,621 70,654,255 1823.6 n.a. LB – 
P3 16p11.2 Del 28,722,783 28,824,859 102.1 n.a. LB – 
Xq28 Del 153,409,765 153,520,551 110.8 n.a. VUS – 
P4 16p11.2 Del 28,824,802 29,040,571 215.8 mat P 613444 
2q37 Del 242,855,645 243,030,854 175.2 n.a. LB 600430 
P5 16p11.2 Dup 29,620,689 30,190,568 569.0 n.a.a P 614671 
P6 16p11.2 Dup 29,624,765 30,199,351 574.6 mat P 614671 
P7 16p11.2 Dup 29,624,765 30,199,351 574.6 mat P 614671 
P8 16p11.2 Dup 29,624,765 30,199,351 574.6 n.a. P 614671 
P9 16p11.2 Del 29,656,684 30,190,568 533.9 n.a.a P 611913 
P10 16p11.2 Del 31,980,001 33,825,000 1845.0 d.n. VUS – 
Xq28 Del 153,409,765 153,520,551 110.8 n.a. VUS – 
bp, basepairs; Kb, kilobase; OMIM, Online Inheritance in Man (https://www.omim.org/); Del, deletion; Dup, duplication; n.a., not available; mat, maternal; d.n., de 
novo; VUS, variant of unknown significance; P, pathogenic; LB, likely benign. 
a For P5 and P9 maternal inheritance was excluded, but the fathers refused testing. 
Fig. 2. Recurrent copy number variations of the short arm of chromosome 16 and the rearrangements of the presented patients. The purple bars denote four 
recurrent CNV regions; red bars indicate deletions, blue bars indicate duplications. (For interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
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not reproduced in a subsequent study; Kctd13 reduction did, however, 
lead to a decreased functional synapse number and reduced synaptic 
transmission in mutant mice. Furthermore, reduced synaptic trans-
mission correlated with increased levels of Ras homolog gene family, 
member A (RhoA - a substrate of the aforementioned ubiquitin ligase 
complex), and was reversed by RhoA inhibition, which might prove 
therapeutically relevant in the future (Escamilla et al., 2017). Possibly 
relevant in regards to seizures is the PRRT2 gene [OMIM *614386 
(Scheffer et al., 2012)], which is linked to a benign epilepsy syndrome 
(OMIM *605751). 
The gene suspected to play a role in the obesity phenotype associated 
with the distal microdeletion is SH2B1 (OMIM *608937), encoding a 
cytoplasmic adaptor protein for various members of the tyrosine kinase 
receptor family, and postulated to enhance hypothalamic leptin sensi-
tivity, thus regulating energy balance, body weight, peripheral insulin 
sensitivity and glucose homeostasis. Alterations of SH2B1 lead to leptin 
and insulin resistance, polyphagia, obesity and type 2 diabetes mellitus 
in mice and humans (Ren et al., 2007; Rui, 2014). LAT (OMIM *602354) 
– encoding a protein that is part of a complex required for T-cell 
development and signaling, and likely has an important role in neuro-
genesis - was proposed as a major driver gene of the mirror HC pheno-
type in the BP2–BP3 rearrangements. Moreover, co-injection of LAT and 
KCTD13 seems to have an additive effect on zebrafish HC, providing 
evidence for genetic interactions between the distal and the proximal 
recurrent 16p11.2 CNV regions (Loviglio et al., 2017a,b). 
5.2. Variants of unknown significance in 16p 
Patient 1 has a 16p12.2 microdeletion containing the 3′ part of OTOA 
(OMIM *607038), a key gene implicated in the pathomechanism of the 
recurrent 16p11.2p12.2 microdeletion syndrome (OMIM #613604). 
Defects of OTOA have been implicated in autosomal recessive and non- 
syndromic hearing loss, and the hearing impairment occasionally seen in 
16p11.2p12.2 microdeletion patients. This syndrome is further charac-
terized by variable minor anomalies, ID/DD, muscular hypotonia, 
feeding difficulties, recurrent ear infections, congenital heart defects 
and behavioral problems, but ASD is uncharacteristic (Battaglia et al., 
2009; Hempel et al., 2009; Okamoto et al., 2014). P1’s clinical presen-
tation does not adhere to this (normal hearing, no history of hearing loss 
in his family, present ASD), and his CNV is much smaller than the typical 
16p11.2p12.2 microdeletion syndrome. A nearly identical deletion has 
recently been reported in a patient referred with short stature, dyslexia, 
pectus excavatum, kyphosis and facial minor anomalies. She inherited it 
from her deaf and severely speech impaired mother, who carried the 
deletion in homozygous form (Tassano et al., 2019). Deletions of similar 
size and gene content can also be found in DECIPHER (Firth et al., 2009), 
Fig. 3. Illustrations of the preformed genetic tests. A: Duplication of proximal 16p11.2 validated by fluorescence in situ hybridization; the three red signals in 
each cell correspond to the 548 kb sized 16p11.2 region identified by a KCTD13 specific FISH probe. B-D: Genetic test results for Patient 10. B: Array CGH results 
showing a 1.85 Mb large deletion between genomic positions 16:31,980,001–33,825,000. C: Haplotypes of the family using microsatellite markers of the proximal 
16p11.2 region. D: Electropherograms of the rs74671405 microsatellite marker. (For interpretation of the references to color in this figure legend, the reader is 
referred to the Web version of this article.) 
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with great variability in reported phenotypic features, however the 
majority have at least one NDD listed (see Supplementary File 3 for 
patient IDs and phenotypes). P1’s other CNV is associated with the 
15q11q13 duplication syndrome (OMIM #608636) characterized by 
normal morphological findings in the majority of patients, learning 
difficulties, global DD, language impairment, seizures and ASD. 
Patient 2’s 16p12.2 duplication encompasses four OMIM genes: the 
cancer related EEF2K (*606968) and CDR2 (*117340) genes, the 
POLR3E (*617815) gene with DNA dependent RNA polymerase activity 
and the disease causing UQCRC2 gene (*191329). The latter encodes a 
protein that is part of the ubiquinol-cytochrome c reductase complex, 
and its mutations are responsible for mitochondrial complex III defi-
ciency. DECIPHER catalogues 8 duplication cases with similar break-
points and nearly identical gene content (Supplementary File 3). At least 
one NDD is listed in the phenotypic information for six out of the eight 
cases, with ASD being the most common (4/8). P2 carries an additional 
large deletion of chromosome 5q13.2, including 6 OMIM genes: OCLN 
(*602876), SERF1A (*603011), NAIP (*600354), GTF2H2 (*601748), 
and spinal muscular atrophy (OMIM #253400) associated SMN1 
(*600354) and SMN2 (*601627). DECIPHER catalogues overlapping 
cases with NDDs (Supplementary File 3). There is a nearly identical Gold 
Standard Variant (gssvL99909) listed in the Database of Genomic Var-
iants (DGV) (MacDonald et al., 2014) with an overall allele frequency of 
1.54%. 
Patient 3’s 16p11.2 deletion encompasses one non-disease associ-
ated OMIM gene, EIF3C (*603916). A search of ClinVar database 
(Landrum et al., 2018) yields three smaller deletions involving EIF3C, 
classified as benign. The DGV lists a gold standard variant (gssvL43531) 
involving only this gene (approximately 40% overlap with P3’s CNV) 
with a frequency of 8.82%. All other ClinVar records that overlap P3’s 
deletion, and overlapping DECIPHER cases as well, either include the 
BP2–BP3 pathogenic region, or are much larger in size. P3’s proximal 
breakpoint is virtually identical with P4’s distal breakpoint (~28,824, 
800). Phenotypic comparison of P3 and P4 shows reverse findings 
regarding BMI (Fig. 1A and B). The CNV seen in P3 is directly upstream 
of the recurrent BP2–BP3 microdeletion and SH2B1 gene, and thus his 
lack of the typical obese phenotype further consolidates the pathogenic 
role of the distal 16p11.2 region and the genes it encompasses. P3 has an 
additional deletion on Xq28, involving the genes encoding the red 
[OPN1LW (OMIM *300822)] and green [OPN1MW (OMIM *300821)] 
photopigments. Various genetic defects of these genes cause color vision 
abnormalities (Deeb, 2005), which, to our knowledge, have not been 
reported in association with the Xq28 CNV. Patient 10 carries an iden-
tical Xq 28 deletion. As of yet, we were unable to perform formal color 
vision testing in the presented patients. 
P10’s 16p deletion contains one OMIM gene, TP53TG3 (*617482), 
which is unlikely to be haploinsufficient according to the DECIPHER 
score (%HI = 94.39), and is not associated with any known disease or 
phenotype. A nearly identical deletion is a DGV Gold Standard Variant 
(gssvL43686), with an overall frequency of 1.35%. We have found two 
similar deletions in patients from international databases (excluding 
those that also encompass one or both of the pathogenic recurrent 
16p11.2 regions; Supplementary File 3). ClinVar database records a VUS 
(nssv581526), which is nearly identical to P10’s deletion with micro-
cephaly and global DD listed in the phenotypic information. DECIPHER 
contains one deletion classified as likely pathogenic (#328130; 
16:30,361,048–33,660,219). The reported features include delayed 
speech and language development, global brain atrophy, global DD, ID, 
gait disturbance, tremor and seizures. This patient has no other CNV, 
however the gene content in their 16p11.2 deletion is much higher 
compared to P10’s. One notable gene is FUS (OMIM *137070), whose 
mutations are associated with amyotrophic lateral sclerosis 6, with or 
without frontotemporal dementia (OMIM #608030) and hereditary 
essential tremor 4 (OMIM #614782) (Merner et al., 2012; Vance et al., 
2009). FUS has high haploinsufficiency potential according to DECI-
PHER and could be a plausible key gene in this patient’s gait disturbance 
and tremor. Another potentially relevant gene is STX1B (OMIM 
*601485), which is associated with early onset generalized epilepsy 
with febrile seizures plus, type 9 (OMIM #616172) (Schubert et al., 
2014), thus linking the deleted region to seizure disorders. Although 
these two patients from the databases are not directly comparable to 
P10, they each presented with various NDDs, and speech development 
was affected in all three. This could suggest that the disturbance of more 
proximal 16p11.2 regions might compromise normal neuro-
development, especially in regards to speech and language, possibly due 
to altered chromatin interactions. 
We believe that the phenotypes of these four patients could be, at 
least partially, attributed to their co-occurring CNVs, in line with the 
second hit model, which states that multiple CNVs (including VUS) can 
have additive, often exacerbating effects on clinical presentation. The 
second hit genomic imbalances are frequently inherited, with maternal 
preference (Girirajan et al., 2010; Redaelli et al., 2019). Girirajan et al. 
also observed an eight-fold increased risk of DD in children carrying two 
large CNVs (Girirajan et al., 2012). P1’s phenotype can be attributed to 
his large 15q11 duplication, however he is at the severe end of the 
phenotypic spectrum, therefore we believe his second hit 16p12.2 
microdeletion plausibly contributed to the striking clinical manifesta-
tion of his NDD. P2 carries a VUS duplication of 16p12.2 and a large 
likely benign 5q13 deletion that have both been sporadically reported in 
association with NDDs. The added affect of these less serious alterations 
could contribute to P2’s developmental and behavioral phenotype. The 
cases of P3 and P10 are less straightforward, as one or both of their 
respective CNVs could be common variants. It is worth mentioning 
however, that common genetic variants have been shown to contribute 
to the risk and variability of severe NDDs in a genome-wide association 
study (Niemi et al., 2018). 
6. Conclusions 
Our cohort of patients with chromosome 16p rearrangements pre-
sented individually variable neuropsychiatric phenotypes with a broad 
spectrum of severity. The presented carriers of the BP2–BP2 and 
BP4–BP5 CNVs corroborate literature data. The neighboring breakpoints 
identified in Patients 3 and 4 support the pathogenicity of the distal 
16p11.2 microdeletions. Patients 1, 2, 3 and 10 highlight the ongoing 
difficulties surrounding the interpretation of genetic variation, genetic 
counseling and anticipatory management. Nevertheless, we present 
these four cases as examples of co-occurring CNVs conferring risk for 
neuropsychiatric phenotypes, primarily concerning speech and 
language. 
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